CRISPR Therapeutics AG (NASDAQ:CRSP) went up by 5.67% from its latest closing price compared to the recent 1-year high of $220.20. The company’s stock price has collected -0.62% of loss in the last five trading sessions. Press Release reported on 04/10/21 that CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
Is It Worth Investing in CRISPR Therapeutics AG (NASDAQ :CRSP) Right Now?
Plus, the 36-month beta value for CRSP is at 2.24. Opinions of the stock are interesting as 12 analysts out of 21 who provided ratings for CRISPR Therapeutics AG declared the stock was a “buy,” while 0 rated the stock as “overweight,” 7 rated it as “hold,” and 2 as “sell.”
The average price from analysts is $151.28, which is $36.24 above the current price. CRSP currently public float of 64.13M and currently shorts hold a 6.58% ratio of that float. Today, the average trading volume of CRSP was 2.15M shares.
CRSP’s Market Performance
CRSP stocks went down by -0.62% for the week, with a monthly drop of -7.45% and a quarterly performance of -36.00%, while its annual performance rate touched 162.73%. The volatility ratio for the week stands at 4.90% while the volatility levels for the past 30 days are set at 6.34% for CRISPR Therapeutics AG. The simple moving average for the period of the last 20 days is -0.48% for CRSP stocks with a simple moving average of 2.51% for the last 200 days.
Analysts’ Opinion of CRSP
Many brokerage firms have already submitted their reports for CRSP stocks, with JMP Securities repeating the rating for CRSP by listing it as a “Mkt Outperform.” The predicted price for CRSP in the upcoming period, according to JMP Securities is $160 based on the research report published on March 04th of the current year 2021.
Needham, on the other hand, stated in their research note that they expect to see CRSP reach a price target of $170, previously predicting the price at $105. The rating they have provided for CRSP stocks is “Buy” according to the report published on December 10th, 2020.
Chardan Capital Markets gave a rating of “Buy” to CRSP, setting the target price at $166 in the report published on December 10th of the previous year.
CRSP Trading at -10.40% from the 50-Day Moving Average
After a stumble in the market that brought CRSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.10% of loss for the given period.
Volatility was left at 6.34%, however, over the last 30 days, the volatility rate increased by 4.90%, as shares sank -9.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.05% lower at present.
During the last 5 trading sessions, CRSP fell by -0.62%, which changed the moving average for the period of 200-days by +58.95% in comparison to the 20-day moving average, which settled at $120.82. In addition, CRISPR Therapeutics AG saw -21.05% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CRSP starting from Bolzon Bradley J PhD, who sale 30,374 shares at the price of $132.37 back on Mar 22. After this action, Bolzon Bradley J PhD now owns 30,375 shares of CRISPR Therapeutics AG, valued at $4,020,667 using the latest closing price.
Bolzon Bradley J PhD, the Director of CRISPR Therapeutics AG, sale 171,003 shares at $149.11 during a trade that took place back on Feb 19, which means that Bolzon Bradley J PhD is holding 168,831 shares at $25,497,840 based on the most recent closing price.
Stock Fundamentals for CRSP
Current profitability levels for the company are sitting at:
- -49295.55 for the present operating margin
The net margin for CRISPR Therapeutics AG stands at -48520.86. The total capital return value is set at -26.08, while invested capital returns managed to touch -25.86. Equity return is now at value -29.00, with -26.00 for asset returns.
Based on CRISPR Therapeutics AG (CRSP), the company’s capital structure generated 3.69 points at debt to equity in total, while total debt to capital is 3.56. Total debt to assets is 3.36, with long-term debt to equity ratio resting at 3.01. Finally, the long-term debt to capital ratio is 2.90.
When we switch over and look at the enterprise to sales, we see a ratio of 11,778.40, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 0.10 and the total asset turnover is 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 18.21.